Left Ventricular Mass Index Predicts Clinical Outcomes in Patients with Obstructive Hypertrophic Cardiomyopathy Undergoing Septal Myectomy
NCT ID: NCT06609382
Last Updated: 2024-09-24
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
490 participants
OBSERVATIONAL
2011-06-01
2020-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Evaluation of Clinical Efficacy and Prognosis in Patients with Hypertrophic Obstructive Cardiomyopathy Through Hemodynamic Modeling Reconstructed by CT
NCT06683872
Evaluation of Right Ventricular Function Post Mitral Valve Operations
NCT05620992
Risk Factors of Postoperative Complications in HCM Patients
NCT04275544
Myocardial Stiffness Evaluation in Patients With Heart Failure With Preserved Ejection Fraction
NCT06196086
AI-based Frailty Assessment Tool for Patients Undergoing Cardiac Surgery
NCT06096922
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
RETROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Obstructive hypertrophic cardiomyopathy who underwent septal myectomy
Patients who had at least one cardiac magnetic resonance examination before surgery.
Patients had a higher left ventricular mass index or not （the exact value is determined by the cut-off value for the clinical outcomes)
Patients were grouped by the cutoff value of left ventricular mass index (LVMI) for all cause death, and the Maximally Selected Rank Statistics method was used to determine the optimal cutoff point of LVMI for death.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Patients had a higher left ventricular mass index or not （the exact value is determined by the cut-off value for the clinical outcomes)
Patients were grouped by the cutoff value of left ventricular mass index (LVMI) for all cause death, and the Maximally Selected Rank Statistics method was used to determine the optimal cutoff point of LVMI for death.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Exclusion Criteria
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Changrong Nie
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Changrong Nie
MD
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Fuwai hospital
Beijing, Beijing Municipality, China
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2022-GSP-GG-29
Identifier Type: OTHER_GRANT
Identifier Source: secondary_id
2020-1315
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.